<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12(2)</volume><submitter>Chiusaroli L</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Methicillin-resistant &lt;i>Staphylococcus aureus&lt;/i> (MRSA), methicillin-resistant coagulase-negative &lt;i>Staphylococci&lt;/i> (MR-CoNS), and vancomycin-resistant &lt;i>Enterococci&lt;/i> (VRE) are increasing worldwide and represent a threat for the limited treatment options in pediatric patients and neonates compared to adults. Recommendations in pediatrics are mainly extrapolated from adults' studies.&lt;h4>Methods&lt;/h4>A literature search for the treatment of these pathogens in children (&lt;18 years old) was conducted in Embase, MEDLINE, and Cochrane Library. Studies reporting data on single-patient-level outcomes related to a specific antibiotic treatment for multidrug resistant (MDR) Gram-positive bacterial infection in children were included. Studies reporting data from adults and c</pubmed_abstract><journal>Antibiotics (Basel, Switzerland)</journal><pagination>261</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9952189</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Therapeutic Options and Outcomes for the Treatment of Children with Gram-Positive Bacteria with Resistances of Concern: A Systematic Review.</pubmed_title><pmcid>PMC9952189</pmcid><pubmed_authors>Barbieri E</pubmed_authors><pubmed_authors>Chiusaroli L</pubmed_authors><pubmed_authors>Di Chiara C</pubmed_authors><pubmed_authors>Mengato D</pubmed_authors><pubmed_authors>Rulli L</pubmed_authors><pubmed_authors>Liberati C</pubmed_authors><pubmed_authors>De Pieri M</pubmed_authors><pubmed_authors>Dona D</pubmed_authors><pubmed_authors>Giaquinto C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Therapeutic Options and Outcomes for the Treatment of Children with Gram-Positive Bacteria with Resistances of Concern: A Systematic Review.</name><description>&lt;h4>Background&lt;/h4>Methicillin-resistant &lt;i>Staphylococcus aureus&lt;/i> (MRSA), methicillin-resistant coagulase-negative &lt;i>Staphylococci&lt;/i> (MR-CoNS), and vancomycin-resistant &lt;i>Enterococci&lt;/i> (VRE) are increasing worldwide and represent a threat for the limited treatment options in pediatric patients and neonates compared to adults. Recommendations in pediatrics are mainly extrapolated from adults' studies.&lt;h4>Methods&lt;/h4>A literature search for the treatment of these pathogens in children (&lt;18 years old) was conducted in Embase, MEDLINE, and Cochrane Library. Studies reporting data on single-patient-level outcomes related to a specific antibiotic treatment for multidrug resistant (MDR) Gram-positive bacterial infection in children were included. Studies reporting data from adults and c</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2025-05-29T19:43:00.486Z</modification><creation>2025-05-29T19:43:00.486Z</creation></dates><accession>S-EPMC9952189</accession><cross_references><pubmed>36830174</pubmed><doi>10.3390/antibiotics12020261</doi></cross_references></HashMap>